ArticleFrontiers in oncology2026
Women with suspected diagnosis of ovarian cancer in Ghana: how much do we know about them?
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Addressing disparities in ovarian cancer care between sub-Saharan Africa and other regions begins with the fundamental question, "Who gets ovarian cancer?" This study aimed to identify the demographic and clinical predictors of cancer among women with ovarian tumours. Methods: We conducted a cross-sectional analysis of women with histology-confirmed ovarian tumour discussed at a multidisciplinary tumour board in a tertiary hospital in Ghana between 2013 and 2024. Descriptive statistics were used to summarise the characteristics of the women, and logistic regression was performed to identify predictors of ovarian cancer. P≤0.05 was considered statistically significant. Results: Of the 496 women whose data were analysed, 74.4% (n=369) had ovarian cancer. Women diagnosed with ovarian cancer were older than those without cancer (median age 50 years (36-60) vs 39 years (26-55), p<0.001). Most women (274, 55.3%) were married; 297 (59.9%) were multiparous; 291 (58.7%) were urbanites; and more women with cancer were unemployed (93 vs 8, p=0.023). Most women (281, 56.7%) reported abdominal distension. Women with cancer had anaemia (p<0.001), hypertension, diabetes, or other comorbidities (p=0.012). Of the 127 benign tumours, mature cystic teratomas (50, 39.4%), mucinous tumours (28, 22.0%), serous tumours (20, 15.7%), and ovarian fibromas (12, 12.9%) were common. Few (30, 7.5%) and 3 (0.8%) had immunohistochemical and genetic tests, respectively. Travel distance of 100 km or more, (aOR 2.82; 95% CI: 1.21-6.56) postmenopausal status (aOR 6.43; 95% CI: 1.98-20.92), symptom duration of 3-6 months (aOR 2.85; 95% CI: 1.36-5.95), anaemia (aOR 3.74; 95% CI: 1.93-7.25) and hypertension, diabetes, or other comorbidities (aOR 3.74; 95% CI: 1.93-7.25) were predictors of ovarian cancer. Other predictors were tumours with a solid component (aOR 12.97; 95% CI: 3.16-53.18), vascular flow on imaging (aOR 9.53; 95% CI: 4.63-19.65), ascites (aOR 3.62; 95% CI: 1.84-7.14) and elevated serum CA-125 levels (aOR 4.48; 95% CI: 2.32-8.62). Conclusion: Most women with ovarian tumours were young, and a significant proportion had benign tumours, highlighting the need for a more thorough diagnostic assessment. Improved gynaecological ultrasound scanning, access to intraoperative pathology consultation and molecular testing will be essential for guiding ovarian cancer care in Ghana.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.